Microbiota-host genetic interactions modulate MASLD risk in PNPLA3^I148M carriers via ceramides and are reversible by targeted microbial interventions.

Authors

Madhuri Haque, Till Robin Lesker, Ulrike Rolle-Kampczyk, Anneleen Segers, Willem M De Vos, Antonio Molinaro, Thriveni Basavanapura, Yazhou Chen, Maria Backhaus, Mohamed Ramadan Mohamed, Lu Jiang, Qusay Salih, Lena Candels, Marcus Henricsson, Agata Bielecka, Sonja Lang, Frank Tacke, Jan G Hengstler, Carolin Victoria Schneider, Münevver Demir, Till Strowig, Martin von Bergen, Kai Markus Schneider, Christian Trautwein

Published in

Gut. Oct 05, 2026. Epub Oct 05, 2026.

Abstract

The factors that determine when genetic susceptibility to metabolic dysfunction-associated steatotic liver disease (MASLD) progresses to clinically significant liver injury remain incompletely understood.
We investigated whether disruption of the intestinal host-microbiota interface acts as a contextual modifier that amplifies PNPLA3^I148M -associated hepatic injury.
We used a dual-hit mouse model combining hepatic Pnpla3^I148M -expression with Nlrp6-deficiency, a model of impaired intestinal mucosal homeostasis, under western-diet conditions. Multi-omics profiling, including metagenomics, metabolomics and transcriptomics, was integrated with analyses in human cohorts (Lifelines, Charité MASLD, Human Phenotype Project). Microbiota-dependent effects were examined using faecal microbiota transplantation (FMT), antibiotic-mediated depletion and targeted intervention with Akkermansia muciniphila or its membrane protein Amuc_1100.
In mice, the combination of Pnpla3^I148M expression and impaired intestinal sensing synergistically exacerbated gut-barrier dysfunction and bacterial encroachment, accompanied by increased portal levels of microbiota-associated metabolites, including long-chain ceramides (Cer(d18:1/16:0), Cer(d18:1/18:0)) and bile acids. These changes were associated with hepatic mitochondrial stress and inflammatory responses. Human carriers with advanced MASLD displayed microbial and metabolic signatures consistent with increased gut-derived metabolic signalling. Restoration of eubiotic microbiota via FMT or Amuc_1100 treatment improved intestinal barrier integrity and attenuated hepatic lipid accumulation in experimental models.
These findings suggest that gut-derived signals resulting from a disrupted intestinal barrier may act as modifiers of PNPLA3^I148M -clinical penetrance by amplifying downstream metabolic and inflammatory responses. By identifying these pathways linking environmental context to genetic susceptibility, this study highlights the host-microbiota interface as a potential target for strategies aimed at limiting MASLD progression in genetically at-risk individuals.

PMID:
42833873
Bibliographic data and abstract were imported from PubMed on 06 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.